Newsroom Archives - Page 12 of 24 - Spectral Medical Inc

Spectral Medical Provides Update on Continued Favorable Tigris Clinical Trial Enrollment

Tigris trial enrollment at 64 patients Crude mortality results continue to exceed expectations TORONTO, Canada – June 20, 2023- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage theranostic company advancing therapeutic options for sepsis...

Spectral Medical Provides Update on Favorable Tigris Clinical Trial Enrollment

Reports significant uptick in enrollment activities Tigris trial enrollment at 61 patients TORONTO, Ontario – May 30, 2023 – Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage theranostic company advancing therapeutic options for sepsis...

Spectral Medical Hosts Successful Investigator Meeting; Expected to Help Bolster Enrollment Activities

Tigris trial enrollment at 60 patients. TORONTO, Ontario – May 24, 2023 – Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today reported hosting an...

Spectral Medical Inc. Announces Director Resignation

TORONTO, Ontario – May 4, 2023 – Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced that Mr. Jim Funk has tendered his resignation from the Board...

Spectral Medical Announces Investor Update Conference Call

TORONTO, Ontario – April 6, 2023 – Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced details for the Company’s 2023 Investor Update conference...

Spectral Medical Announces the Opening of Two Additional Tigris Clinical Trial Sites

Reaches 16 total clinical trial sites for Tigris and expects two more opening around the end of Q1 TORONTO, Ontario – March 9, 2023 – Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for...

« Older Entries

Next Entries »

EAA™ and PMX are licensed and available for use in Canada. PMX is not approved for clinical use in the USA, and is currently undergoing the PMA (Premarket approval) process. EAA™ is FDA cleared for use in the USA. The information presented herein is region specific. Please contact Spectral Medical Inc.to obtain appropriate product information for your country.